Skip to main content

New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships

Buy Article:

$63.00 plus tax (Refund Policy)

In the last 15 years, calcium channel blockers have been widely used for treating cardiovascular diseases. These agents are a heterogeneous group of drugs with differing cardiovascular effects, and are effective in the treatment of angina and hypertension. These synthetic compounds bind separately with receptor sites located in or near the calcium channel, at molecular sites still to be fully identified.

Verapamil, nifedipine and diltiazem are the most representative calcium channel blockers and used as prototypes for the design and development of new anticalcium molecules with potential efficacy and reduced toxic effects.

There are three different types of voltage-operated calcium channels (VOCs): L-type, T-type and N-type, which are considered extra-cellular, but some anti-calcium agents as bepridil possess potential intracellular calcium activity. Many synthetic compounds containing heterocyclic ring in their structures have attracted considerable interest since current studies revealed their mechanisms and sites of action.

This article reviews the new advances in the calcium channel antagonist group, showing new structures with longer-acting and higher vascular selectivity.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: calcium channel; calcium channel antagonists; calcium channel blockers; cardiovascular effects; hypertension; voltage-operated calcium channels

Document Type: Review Article

Publication date: 2003-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more